Sanofi- aventis: A Promising R&D Portfolio, Well Positioned to Deliver Future Growth

PARIS, Sept. 17, 2007--Sanofi-aventis today made announced it plans to have 31 potential submissions by the end of 2010. The company released a detailed analysis on its pipeline.

Significant progress in pipeline

§ Important clinical results and 31 potential submissions by the end of 2010.

§ 48 projects in advanced phases (phase IIb/III).

§ A well balanced portfolio between our major therapeutic areas.

High-potential projects in our spheres of excellence

THROMBOSIS

Possible successor to Lovenox® and an alternative to antivitamin K

AVE5026 (new ultra low molecular weight heparin): Phase IIb results demonstrated potentially greater efficacy than Lovenox® with a comparable safety profile. Large-scale phase III program to start. Anticoagulant with best-in-class potential.

Biotinylated idraparinux (selective, neutralizable factor Xa synthetic inhibitor): Comparative study versus anti-vitamin K due to start at end 2007 targeting a major clinical need in anti-coagulation – prevention of stroke and systemic embolism in cases of atrial fibrillation.

DIABETES

A portfolio that targets all stages of the disease while offering relevant solutions for concomittant comorbidities, in particular overweight

Rimonabant (the first CB1 antagonist): Significant expansion of the clinical program in type 2 diabetes, with more than 5,700 patients, including a comparative study versus the most recently-approved type 2 diabetes treatment due to start in the first quarter of 2008. Worldwide submission in this indication scheduled for 2009.

AVE0010 (GLP-1 agonist): Very encouraging phase IIb results. Once a day injection demonstrated efficacy. Start of a phase III program in the first half of 2008. Prolonged release formulation due to start phase II trials in the first half of 2008.

AVE2268 (SGLT-2 inhibitor): Ideal profile for use in combination with other anti-diabetics. Phase IIb results due in the first half of 2008, followed by rapid start of phase III.


Please see the attachment for the complete press release.

Press Relations
Tel (33) 1 53 77 44 50
Fax (33) 1 53 77 46 22

Posted: September 2007


View comments

Hide
(web4)